It is likely that MMR proficient tumors were heterogeneous in earlier studies based on the identification of MMR deficiency alone [5,6,7,8,9,10,11], which could explain the inconsistent findings on the association of MMR status with patient outcome. This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.